Published on 9/13/2006 in the Prospect News Biotech Daily.
NuPathe completes $15 million series A financing round
By Lisa Kerner
Charlotte, N.C., Sept. 13 - NuPathe Inc. completed a $15 million round of series A private equity financing to support the company's clinical programs for therapeutic products to treat migraine and other central nervous system disorders.
Birchmere Ventures and BioAdvance Ventures co-led the financing round with participation from Safeguard Scientifics, Inc. and other institutional investors, according to a company news release.
NuPathe is a specialty pharmaceutical company based in Conshohocken, Pa.
Issuer: | NuPathe Inc.
|
Issue: | Series A private equity financing
|
Amount: | $15 million
|
Investors: | Birchmere Ventures and BioAdvance Ventures (co-leads), Safeguard Scientifics, Inc., other institutional investors
|
Announcement date: | Sept. 13
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.